+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Trends in prostate-specific antigen testing from 1995 through 2004



Trends in prostate-specific antigen testing from 1995 through 2004



Archives of Internal Medicine 167(22): 2497-2502



Background: The utility of the prostate-specific antigen (PSA) test to screen for prostate cancer has been widely debated for several years. Whether PSA testing rates have changed during this period of controversy is not well known.Methods: We examined the National Ambulatory Medical Care Survey (1995-2004) of visits to primary care providers by healthy men aged 35 years or older. We examined visits by calendar year and compared the years 2000 through 2004 with the years 1995 through 1999. We also examined visits by men in the overall population and in particular subgroups.Results: Primary care physicians ordered PSA tests in 4.7% of all visits in 1995 and in 7.0% of all visits in 2004 (P=.03). In multivariate analysis, the odds of a primary care physician ordering a PSA test during any clinic visit increased 8%( odds ratio [ OR], 1.08; 95% confidence interval [CI], 1.04-1.12; P <.001) per year from 1995 through 2004. The increase was more pronounced among men making visits for general medical examinations (11.2% in 1995 vs 32.3% in 2004; P=.003). Comparing the period 2000-2004 with the period 1995-1999, the odds of PSA testing increased in nearly all subgroups but most dramatically in black men ( OR, 2.3; 95% CI, 1.4-3.8; P=.002) and in men 35 through 49 years of age ( OR, 1.8; 95% CI, 1.3-2.6; P=.001).Conclusion: In a nationally representative sample, we found that despite the lack of clear evidence of benefit, PSA testing for prostate cancer screening has increased dramatically, especially among black men and younger men.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 022030201

Download citation: RISBibTeXText

PMID: 18071173

DOI: 10.1001/archinte.167.22.2497


Related references

Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction: A registry-based study in southeastern Netherlands, 1971-1995. European Journal of Cancer 34(5): 705-709, 1998

Prostate-specific antigen testing in the United States in 1995-96 Men aged 70 and over are still a target. JGIM 13(Suppl. 1): 35, 1998

Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml. Journal of Urology 158(2): 502-504, 1997

Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing. Journal of Urology 196(4): 1047-1052, 2016

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. Journal of the National Cancer Institute 91(12): 1033-1039, 1999

Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Irish Journal of Medical Science 179(1): 43-49, 2010

A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. Bju International 109(11): 1627-1635, 2012

A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. Journal of Urology 185(5): 1650-1655, 2011

Effect of percent free prostate-specific antigen measurement on improving the specificity of serum prostate-specific antigen testing in Taiwanese patients. Journal of the Formosan Medical Association 100(2): 113-119, 2001

Radiotherapy for localized prostate carcinoma: The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen. Cancer 79(2): 328-336, 1997

A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate-specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. Clinical Chemistry 45(3): 422-424, 1999

Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis. European Urology 39(1): 57-64, 2001

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Research 61(15): 5857-5860, 2001